Friday, April 24, 2026-A multicentre clinical study has reported encouraging long-term results for a gene therapy targeting OTOF-related deafness, a rare genetic form of hearing loss present from birth. Researchers followed patients for up to 2.5 years after treatment and found sustained improvements in hearing ability in most participants.
The therapy works by delivering a functional copy of the OTOF gene directly into the inner ear using a harmless viral vector. The OTOF gene is essential for transmitting sound signals from the inner ear to the brain, and mutations in it typically cause severe to profound hearing loss from infancy. After treatment, many patients showed measurable gains in hearing thresholds and improved ability to detect and interpret speech sounds.
Over the follow-up period, the improvements were largely stable, with some patients continuing to show gradual gains in auditory performance. Importantly, no serious long-term safety concerns were reported, although researchers emphasize that ongoing monitoring is still needed to confirm durability and broader applicability.
Experts describe the findings as a significant step forward for genetic hearing loss treatments, suggesting that early-stage gene therapies may offer lasting benefits for conditions once considered irreversible. However, they also caution that larger trials will be necessary before the treatment becomes widely available.
0 Comments